Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

INKmune

Cell therapy (NK cells) · Immune activation · developed by Inmune Bio

Phase 1/2 Most advanced trial (none active)
INMB Developer
1 Registered trials

What is INKmune?

INKmune is a suspension of INB16 cells rendered replication incompetent, designed to prime and activate natural killer (NK) cells in vivo to achieve tumor cell lysis. It is being studied in cancer, including metastatic castration-resistant prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (NK cells)
Mechanism
Immune activation
Pathways
NK cell priming and activation
Therapy area
Oncology
Developer
Inmune Bio, Inc. (INMB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06056791 Phase 1/2 Cancer Completed INMB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

CancermCRPCMetastatic Castration-resistant Prostate Cancer

More from Inmune Bio

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the INMB page.

Follow INMB, the company behind INKmune

See INMB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

INMB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.